Gilead sets a price for its coronavirus treatment — Pfizer's newest digital health bet — Reopenings reversed
States and cities are starting to pause or reverse their plans to reopen as case counts spike. Here's the latest. official price of Gilead Sciences'
It clocks in at a price of $3,120 for a five-day treatment course, or $520 a vial, Andrew Dunn reports.That's at least the price set for America's private insurers. For governments and organizations like the Department of Veteran Affairs, the price will be 33% lower, at $2,340 for a five-day treatment course.
The biotech giant Gilead just laid out its pricing strategy for the first effective coronavirus treatment, and it's charging up to $520 a vial for remdesivir76712479Advertisement
A tiny startup just won a crucial deal with $175 billion drug giant Pfizer, and it shows how apps are becoming the next frontier as Big Pharma pushes beyond pills
- Pfizer just cut a deal with the digital-health startup
SidekickHealth, which uses a mobile app to help patients eat better, sleep better, and stick to their medications.
- The deal is worth more than $8 million, a person close to the transaction said.
- Sidekick's app is designed to help people manage their chronic conditions and improve their health.
Investors just put $18 million into a GV-backed startup taking the opposite approach to healthcare data storage as Amazon, Microsoft, and Google
- Research startup Owkin just raised an additional $18 million from investors including Mubadala Capital and existing investor Bpifrance, an investment bank.
- Owkin's platform helps researchers learn from each other's data without actually sharing patient information, according to the company.
- It's being used to solve coronavirus mysteries and runs counter to storage solutions offered by giant tech firms like Amazon, Google, and Microsoft.
More stories we're reading:
- Pharmaceutical giants have added $51 billion to their market value in 2020 as they scramble to develop a coronavirus vaccine (Markets Insider)
- A look inside a Houston hospital as it battles a surge of coronavirus cases (The New York Times)
- California, whose coronavirus response was hailed as a success story, is now seeing 5,000-plus cases each day. Here's what went wrong. (Business Insider)
- The FDA rejected Intercept Pharmaceutical's NASH drug (Stat News)
Thanks for reading Dispensed Daily, a daily version of my weekly Dispensed email. Let me know what you think, and what you'd like to see out of a daily healthcare newsletter. You can reach me email@example.com.-LydiaAdvertisement
- Zomato turns 12 – from a weekend project to a $3 billion company, here’s the startup’s journey over the years
- Most adults infected with COVID-19 in South Africa are asymptomatic cases: official
- 936 new COVID-19 cases in Assam; eight more die
- 156 fresh cases in Jharkhand, COVID-19 tally now 3,518
- 755 new COVID-19 cases take Odisha's tally to 11,956